[Serrazyme] [Research studies] [References]

WrinklyMedic home



Serrazyme Studies

Using the power of nature to reduce inflammation and pain, without side effects.

Histologic studies reveal powerful anti-inflammatory effects of this naturally occurring enzyme Serrapeptase (SP).

Serrapeptase is an anti-inflammatory, proteolytic enzyme isolated from the micro-organism, Serratia E15. This enzyme is naturally present in the silkworm intestine and is processed commercially today through fermentation.


Using the power of nature to reduce inflammation and pain, without side effects.

The silkworm has a symbiotic relationship with the Serratia microorganisms in its intestines. The enzymes secreted by the bacteria in silkworm intestines have a specific affinity to avital tissue and have no detrimental effect on the host's living cells.

A review of the scientific literature, including a series of controlled, clinical trials with large patient groups, suggests that Serrapeptase is useful for a broad range of inflammatory conditions.

If one considers the fact that anti-inflammatory agents are among the most widely prescribed drugs, the use of a safe, proteolytic enzyme such as SP would be a welcome addition to the physician's armamentarium of physiologic agents.


By dissolving a small hole in the silkworm's protective cocoon (avital tissue), the winged creature is able to emerge and fly away. The discovery of this unique biological phenomenon led researchers to study clinical applications of the SP enzyme in man.




In addition to its widespread use in arthritis, fibrocystic breast disease and carpal tunnel syndrome, researchers in Germany have used SP for atherosclerosis. SP helps to digest atherosclerotic plaque without harming the healthy cells lining the arterial wall.


Today, researchers consider atherosclerosis an inflammatory condition similar to other degenerative diseases. Some immunologists are even categorizing atherosclerosis as a benign tumour. Hardening and narrowing of the arterial wall is a cumulative result of microscopic trauma; inflammation occurs in the presence of oxidized lipids. SP doesn't interfere with the synthesis of cholesterol in the body, but helps clear avital tissue from the arterial wall.

Supported by Research, Study and Clinical Trial References



It is important to note that cholesterol in its pure state is an antioxidant and a necessary component of the major organ systems in the body. The use of medications, which block cholesterol biosynthesis, may eventually damage the liver and compromise anti-oxidant status of the eyes, lungs and other soft tissues.


SP has been admitted as a standard treatment in Germany and other European countries for the treatment of inflammatory and traumatic swellings.  In one double-blind study of SP conducted by Esch et al at the German State Hospital in Dim, 66 patients with fresh rupture of the lateral ligament treated surgically were divided in three randomised groups. In the group receiving the test substance, the swelling had decreased by 50% on the third postoperative day, while in the other two control groups (elevation of the leg, bed rest, with or without the application of ice), no reduction in swelling had occurred at that time.




The difference was of major statistical significance. Decreasing pain correlated for the most part with the reduction in swelling. The patients receiving SP became pain-free more rapidly than the control groups. By the 10th day, all patients were free of pain in the SP-treated group. The therapeutic daily dose was 1-2 tablets (5 mg) 3 times daily.




In another double-blind research study, the anti-inflammatory enzyme, SP, was evaluated in a group of 70 patients with evidence of cystic breast disease.




These patients were randomly divided into a treatment group and a placebo group. SP was noted to be superior to placebo for improvement of breast pain, breast swelling and induration with 85.7% of the patients receiving SP reporting moderate to marked improvement. No adverse reactions were reported with the use of SP. The use of enzymes with fibrinolytic, proteolytic and anti-edemic activities for the treatment of inflammatory conditions of the ear, nose and throat has gained increasing support in recent years.


In a third double-blind study, 193 subjects suffering from acute or chronic ear, nose or throat disorders were evaluated.




Treatment with SP lasted 7-8 days, two 5 mg tabs, t.i.d. After 3-4 days treatment, significant symptom regression was observed in the SP-treated group, while this was not noted in the control group. Patients suffering from laryngitis, catarrhal rhinopharyngitis and sinusitis noted markedly rapid improvement. The physicians' assessments of efficacy of treatment were excellent or good for 97.3% of patients treated with SP compared with only 21.9% of those treated with placebo.


In a similar study of chronic bronchitis, conducted by a team of otolaryngolosits, the SP-treated group showed excellent results compared with the placebo group in the improvement of loosening sputum, frequency of cough and expectoration. Other improvements included the posterior nasal hydro rhea and rhinos enosis.




Top of page

The administration of SP reduces the viscosity of the nasal mucus to a level at which maximal transport can be achieved. It has also been demonstrated that the simultaneous use of the peptidase and an antibiotic results in increased concentrations of the antibiotic at the site of the infection.


The mechanisms of action of SP, at the sites of various inflammatory processes consist fundamentally of a reduction of the exudative phenomena and an inhibition of the release of the inflammatory mediators. This peptidase induces fragmentation offibrinose aggregates and reduces the viscosity of exudates, thus facilitating drainage of these products of the inflammatory response and thereby promoting the tissue repair process.

Studies suggest that SP has a modulatory effect on specific acute phase proteins that are involved in the inflammatory process.




This is substantiated by a report of significant reductions in C3 and C4 complement, increases in opsonizing protein and reductions in concentrations of haptoglobulin, which is a scavenger protein that inhibits lysosomal protease.



Carpal tunnel syndrome is a form of musculol-igamentous strain caused by repetitive motion injury. Individuals who work at keyboard terminals are particularly susceptible to this condition. While surgery has been considered the first line treatment for carpal tunnel syndrome, recent studies reveal that the use of anti-inflammatory enzymes (e.g. SP and bromelain) in conjunction with vitamins B2 and B6 are also effective.




The use of non-invasive, nutritional approaches to the treatment of this common condition will become more important as a generation of keyboard operators approach retirement.


Several research groups have reported the intestinal absorption of SP. SP is well absorbed orally when formulated with an enteric coating. It is known that proteases and peptidases are only absorbed in the intestinal area.


These enzymes are mobilized directly to the blood and are not easily detectible in urine. Other enzymes with structural similarities have been reported to be absorbed through the intestinal tract, Chymotrypsin is transported into the blood from the intestinal lumen.




Horseradish peroxidase can cross the mucosal barrier of the intestine in a biologically and immunologically active form. Several studies have appeared so far which refer to the systemic effects of orally given proteases and peptidases (e.g. SP), such as repression of oedema and repression of blood vessel permeability induced by histamine or bradykinin.


These enzymes also affect the kallikrein-kinin system and the complement system, thus modifying the inflammatory response. In vitro and in vivo studies reveal that SP has a specific, anti-inflammatory effect, superior to that of other proteolytic enzymes.





Top of page











Problems or comments on this site ?

Click here for Contact Information